EVAX furnishes 6-K with EVX-01 phase 2 75% ORR headline

Rhea-AI Filing Summary

Evaxion A/S furnished a Form 6-K announcing a press release titled “Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01.” The press release, dated October 17, 2025, is provided as Exhibit 99.1.

The report states this Form 6-K is incorporated by reference into Evaxion’s effective registration statements, including Forms S-8, F-3, and F-1. The filing highlights the reported 75% objective response rate for EVX-01 as described in the press release title.

Insights

Biotech clinical-trial analyst

Evaxion furnished a press release citing a 75% ORR in an EVX-01 phase 2 trial.

Evaxion A/S filed a 6-K that includes a press release dated October 17, 2025 reporting a 75% objective response rate for its AI-designed personalized cancer vaccine EVX-01 in a phase 2 setting. The 6-K also incorporates this information by reference into existing U.S. registration statements.

The document excerpt provides the headline result but not study details such as sample size, control arm, durability, or safety. Interpretation therefore depends on the underlying press release and future regulatory or clinical disclosures.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On October 17, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: October 17, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion (EVAX) announce in this Form 6-K?

Evaxion furnished a press release reporting a 75% Objective Response Rate in a phase 2 trial of its personalized cancer vaccine EVX-01.

When was the Evaxion press release issued?

The press release was issued on October 17, 2025 and is included as Exhibit 99.1.

Which exhibit contains the press release for Evaxion’s EVX-01 update?

The press release is furnished as Exhibit 99.1.

Which registration statements does this 6-K incorporate by reference for EVAX?

It is incorporated by reference into Forms S-8 (333-255064), F-3 (333-265132), F-1 (333-266050, 333-276505, 333-279153, 333-283304), and F-3 (333-285778).

What product is highlighted in Evaxion’s update?

The update highlights EVX-01, an AI-designed personalized cancer vaccine.

Does the filing provide detailed clinical data for the 75% ORR?

The excerpt cites the headline result in the press release title; detailed data are not included in the excerpt.